[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.208.7. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 6, 1906

Standardization of Suprarenal Products.

Author Affiliations

Parke, Davis & Co. General Manager.

JAMA. 1906;XLVII(14):1116. doi:10.1001/jama.1906.02520140052018

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

Detroit, Sept. 25. 1906.

To the Editor:  —A very erroneous impression is likely to he made on the minds of your numerous readers by vour editorial on page 944 of The Journal, September 22. To 19 men out of 20 the clear meaning of the article is that manufacturers do not standardize their suprarenal preparations, whereas, speaking emphatically for ourselves, we do standardize these products, with special reference to our adrenalin and adrenalin solution, ointment and inhalant. We have always done so. In The Journal as far back as 1902 (see page 150, Jan. 18, 1902), our exact method of standardization was set forth in the fullest detail by our chief pharmacologist, Dr. E. M. Houghton.We have no objection to government supervision over the suprarenal preparations of the market; some of them need it. But the very thing which you are urging we have performed systematically ever since we

First Page Preview View Large
First page PDF preview
First page PDF preview
×